{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'trivalent/quadrivalent influenza) during this study, and within the next 8 weeks from', 'Visit 14 (see Section 9.3.1.2 for details).', '-', 'Blood samples for post-vaccination antibody titers for the patient(s) who received', 'vaccination (ie, any tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent', 'influenza) during this study, and within the previous 6 weeks prior to Visit 14', '(see Section 9.3.1.2 for details).', 'Call IVRS/IWRS to register visit and obtain treatment kit number', 'Dispense and administer IMP', '-', 'Patients will be monitored at the study site for a minimum of 30 minutes after the', 'injection.', '-', 'Dispense Home Dosing Diary parent(s)/caregiver(s)/legal guardian(s) willing and', 'trained to perform home-administration of IMP-injection, and provide instructions on', 'preparation, injection and dose. And review the diary for home dosing. Re-check the', 'instructions on home-administration and dosing and dispense Home Dosing Diary, as', 'applicable.', 'For parent(s)/caregiver(s)/legal guardian(s) unable or unwilling to administer IMP:', 'Arrangements must be made for the patient to receive IMP injections at the study site', 'as unscheduled visits, or for qualified site personnel and/or a professional caregiver to', 'administer IMP at home at q2w intervals.', 'Remind arent(s)/caregiver(s)/legal guardian(s) to use salbutamol/albutero. or', 'levosalbutamol/levalbuterol as reliever medication throughout the study. Instruct them to', 'record usage in the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to continue their stable', 'dose of ICS in combination with a second controller as used during the Screening Period', 'and them patient to record daily usage in the electronic diary.', 'Remind patient and their parent(s)/caregiver(s)/legal guardian(s) to withhold', 'bronchodilators according to their action duration, for example, withholding the last dose', 'of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding the', 'last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at', 'least 24 hours. This will be verified before performing the PEF measurements.', 'Schedule a site visit 4 weeks ( 3 days) and ask patient to come at approximately the same', 'time of this visit', '10.1.12', 'Visit 20 (Week 36 [+ 3 days])', 'Check compliance to IMP; record all concomitant medication use; inquire about', 'AEs/SAEs and background asthma therapy tolerability', 'Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature, weight,', 'and height)', 'Obtain urine for urinalysis (dipstick)', 'Property of the Sanofi Group - strictly confidential', 'Page 92', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Assess menstruation status and perform urine dipstick pregnancy test for female patients', 'of childbearing potential (who have commenced menstruating)', 'Administer ACQ-7', 'Administer all additional PROs:', 'PAQLQ(S)-IA, PRQLQ-IA, and PACQLQ', 'Administer HCRU', 'Measure exhaled nitric oxide', '-', 'Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast', 'of >1 hour.', 'Perform spirometry', '-', 'Spirometry will be performed at approximately the same time of last visit after a wash', 'out period of bronchodilators according to their action duration, for example,', 'withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at', 'least 6 hours, withholding the last dose of LABA for at least 12 hours, and withholding', 'the last dose of LAMA for at least 24 hours. This will be verified before performing', 'the PEF measurements.', '-', 'Post-bronchodilator FEV1 should be determined.', 'Download electronic diary/PEF meter and remind patient to bring the device to the next', 'visit', 'Perform blood sampling for the following tests:', '-', 'Clinical laboratory testing (hematology/biochemistry)', '-', 'Blood samples for post-vaccination antibody titers for the patient(s) who received', 'vaccination (ie, any tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent', 'influenza) during this study, and within the previous 6 weeks prior to Visit 20', '(see Section 9.3.1.2 for details).', 'Call IVRS/IWRS to register visit and obtain treatment kit number', 'Dispense and administer IMP', '-', 'Patients will be monitored at the study site for a minimum of 30 minutes after the', 'injection.', '-', 'Dispense Home Dosing Diary parent(s)/caregiver(s)/legal guardian(s) willing and', 'trained to perform home-administration of IMP-injection, and provide instructions on', 'preparation, injection and dose. And review the diary for home dosing. Re-check the', 'instructions on nome-administration and dosing and dispense Home Dosing Diary, as', 'applicable.', '-', 'For parent(s)/caregiver(s)/legal guardian(s) unable or unwilling to administer IMP:', 'Arrangements must be made for the patient to receive IMP injections at the study site', 'Property of the Sanofi Group - strictly confidential', 'Page 93', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}